| Acute lymphocytic leukemia
Asparlas vs Besponsa
Side-by-side clinical, coverage, and cost comparison for acute lymphocytic leukemia.Deep comparison between: Asparlas vs Besponsa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBesponsa has a higher rate of injection site reactions vs Asparlas based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Besponsa but not Asparlas, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Asparlas
Besponsa
At A Glance
IV infusion
Every 21 days
Pegylated L-asparaginase
IV infusion
Days 1, 8, and 15 per cycle
CD22-directed antibody-drug conjugate
Indications
- Acute lymphocytic leukemia
- Acute lymphocytic leukemia
Dosing
Acute lymphocytic leukemia 2,500 units/m2 intravenously no more frequently than every 21 days.
Acute lymphocytic leukemia Cycle 1: 1.8 mg/m2/cycle as 0.8 mg/m2 on Day 1 and 0.5 mg/m2 on Days 8 and 15 (21-day cycle, extendable to 28 days); subsequent cycles (CR/CRi): 1.5 mg/m2/cycle as 0.5 mg/m2 on Days 1, 8, and 15 (28-day cycle); subsequent cycles (non-CR/CRi): 1.8 mg/m2/cycle as 0.8 mg/m2 on Day 1 and 0.5 mg/m2 on Days 8 and 15 (28-day cycle); administered by IV infusion over 1 hour with premedication (corticosteroid, antipyretic, antihistamine).
Contraindications
- History of serious hypersensitivity reactions, including anaphylaxis, to pegylated L-asparaginase therapy
- History of serious pancreatitis during previous L-asparaginase therapy
- History of serious thrombosis during previous L-asparaginase therapy
- History of serious hemorrhagic events during previous L-asparaginase therapy
- Severe hepatic impairment
—
Adverse Reactions
Most common Elevated transaminase, bilirubin increased, pancreatitis, abnormal clotting studies, diarrhea, hypersensitivity, embolic and thrombotic events, sepsis, dyspnea, hemorrhages, fungal infection, pneumonia, arrhythmia, cardiac failure
Serious Hypersensitivity, pancreatitis, thrombosis, hemorrhage, hepatotoxicity including veno-occlusive disease
Postmarketing Veno-occlusive disease (hepatic)
Most common (>=20%) Thrombocytopenia, neutropenia, infection, anemia, leukopenia, fatigue, hemorrhage, pyrexia, nausea, headache, febrile neutropenia, transaminases increased, abdominal pain, gamma-glutamyltransferase increased, hyperbilirubinemia
Serious Infection, febrile neutropenia, hemorrhage, abdominal pain, pyrexia, veno-occlusive disease (VOD), fatigue
Pharmacology
Pegylated L-asparaginase enzyme that depletes plasma asparagine by catalyzing its conversion to aspartic acid and ammonia; leukemic cells with low asparagine synthetase expression depend on exogenous asparagine for survival and are killed by its depletion.
CD22-directed antibody-drug conjugate (ADC); inotuzumab binds CD22-expressing tumor cells, enabling internalization and intracellular release of N-acetyl-gamma-calicheamicin dimethylhydrazide, which induces double-strand DNA breaks leading to cell cycle arrest and apoptotic cell death.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Asparlas
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Besponsa
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Asparlas
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Besponsa
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Asparlas
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Besponsa
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Asparlas Patient Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Acute Lymphoblastic Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AsparlasView full Asparlas profile
BesponsaView full Besponsa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.